α-Arylation of alkylamines with sulfonylarenes through a radical chain mechanism
作者:Yuko Ikeda、Ryota Ueno、Yuto Akai、Eiji Shirakawa
DOI:10.1039/c8cc03604g
日期:——
In the presence of a substoichiometric amount of a tert-butoxy radical precursor, the reaction of alkylamines with sulfonylarenes was found to give α-arylated alkylamines through homolyticaromaticsubstitution, where a radical chain is operative.
<i>tert</i>
-Butoxy-Radical-Promoted α-Arylation of Alkylamines with Aryl Halides
作者:Ryota Ueno、Yuko Ikeda、Eiji Shirakawa
DOI:10.1002/ejoc.201700548
日期:2017.8.2
In the presence of a tert-butoxy radical precursor, the reaction of alkylamines with aryl halides was found to give alpha-arylated alkylamines through homolytic aromaticsubstitution of the halogen atoms.
α-arylation with sulfonylarenes having an azole, azine, and benzenenucleus. The α-arylation was scaled up using an electrolysis flow cell. Mechanistic studies show that anodic oxidation of an alkylamine with a sulfinate as a mediator followed by deprotonation gives an α-aminoalkyl radical, which undergoes homolytic aromatic substitution (HAS) on a sulfonylarene to give the corresponding α-arylalkylamine
[EN] COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR<br/>[FR] POLYTHÉRAPIE COMPRENANT UN INHIBITEUR DE MAT2A ET UN INHIBITEUR DE PRMT DE TYPE II
申请人:[en]IDEAYA BIOSCIENCES, INC.
公开号:WO2022256806A1
公开(公告)日:2022-12-08
Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.